Literature DB >> 22956738

Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread.

Tanel Mahlakõiv1,2, Daniel Ritz3, Markus Mordstein1,2, Marta L DeDiego4, Luis Enjuanes4, Marcel A Müller3, Christian Drosten3, Peter Staeheli2.   

Abstract

STAT1-deficient mice are more susceptible to infection with severe acute respiratory syndrome coronavirus (SARS-CoV) than type I interferon (IFN) receptor-deficient mice. We used mice lacking functional receptors for both type I and type III IFN (double knockout, dKO) to evaluate the possibility that type III IFN plays a decisive role in SARS-CoV protection. We found that viral peak titres in lungs of dKO and STAT1-deficient mice were similar, but significantly higher than in wild-type mice. The kinetics of viral clearance from the lung were also comparable in dKO and STAT1-deficient mice. Surprisingly, however, infected dKO mice remained healthy, whereas infected STAT1-deficient mice developed liver pathology and eventually succumbed to neurological disease. Our data suggest that the failure of STAT1-deficient mice to control initial SARS-CoV replication efficiently in the lung is due to impaired type I and type III IFN signalling, whereas the failure to control subsequent systemic viral spread is due to unrelated defects in STAT1-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956738     DOI: 10.1099/vir.0.046284-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  30 in total

Review 1.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

2.  Low type I interferon response in COVID-19 patients: Interferon response may be a potential treatment for COVID-19.

Authors:  Ahmed Abdulwahid Salman; Mohammed Hussein Waheed; Akeel Abd Ali-Abdulsahib; Zeenah Weheed Atwan
Journal:  Biomed Rep       Date:  2021-03-09

Review 3.  What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

Authors:  Thomas R O'Brien; Sarah S Jackson
Journal:  J Interferon Cytokine Res       Date:  2019-06-04       Impact factor: 2.607

Review 4.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

5.  PharmGKB summary: peginterferon-α pathway.

Authors:  Scott R Shuldiner; Li Gong; Andrew J Muir; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-09       Impact factor: 2.089

6.  Impact and regulation of lambda interferon response in human metapneumovirus infection.

Authors:  Ma Del Rocío Baños-Lara; Lindsey Harvey; Alexander Mendoza; Dawn Simms; Vladimir N Chouljenko; Nobuko Wakamatsu; K Gus Kousoulas; Antonieta Guerrero-Plata
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

Review 7.  Interferon-λs: special immunomodulatory agents and potential therapeutic targets.

Authors:  Ya-wen Zheng; Hui Li; Jin-pu Yu; Hua Zhao; Shizhen Emily Wang; Xiu-bao Ren
Journal:  J Innate Immun       Date:  2012-11-30       Impact factor: 7.349

Review 8.  Interferon-λ: Immune Functions at Barrier Surfaces and Beyond.

Authors:  Helen M Lazear; Timothy J Nice; Michael S Diamond
Journal:  Immunity       Date:  2015-07-21       Impact factor: 31.745

Review 9.  The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections.

Authors:  Adrian Egli; Deanna M Santer; Daire O'Shea; D Lorne Tyrrell; Michael Houghton
Journal:  Emerg Microbes Infect       Date:  2014-07-16       Impact factor: 7.163

Review 10.  Coronavirus virulence genes with main focus on SARS-CoV envelope gene.

Authors:  Marta L DeDiego; Jose L Nieto-Torres; Jose M Jimenez-Guardeño; Jose A Regla-Nava; Carlos Castaño-Rodriguez; Raul Fernandez-Delgado; Fernando Usera; Luis Enjuanes
Journal:  Virus Res       Date:  2014-08-02       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.